Skip to main content

Table 1 Susceptibility of XMRV and HIV-1 to reverse transcriptase inhibitors.

From: Susceptibility of the human retrovirus XMRV to antiretroviral inhibitors

Inhibitor classb

Inhibitorc

EC50(μM)a

  

HIV-1NL4-3

XMRVVP62+LtatSNd

XMRV22Rv1+LtatSNd

NRTI

AZT

0.10 ± 0.05

0.12 ± 0.03 (1)

0.06 ± 0.02 (1)

 

AZddG

0.71 ± 0.01

1.1 ± 0.1 (2)

2.7 ± 0.7 (4)

 

AZddA

2.0 ± 0.9

1.6 ± 0.4 (1)

3.2 ± 1.2 (2)

 

tenofovir

3.5 ± 0.9

5.8 ± 3.2 (2)

5.3 ± 3.8 (2)

 

adefovir

14 ± 2

9.5 ± 3.7 (1)

7.0 ± 0.8 (0.5)

 

D4T

0.99 ± 0.53

34 ± 22 (34)

13 ± 1 (13)

 

ddI

1.79 ± 0.04

43 ± 23 (24)

43 ± 12 (24)

 

abacavir

3.6 ± 1.9

94 ± 54 (26)

66 ± 39 (18)

 

3TC

0.35 ± 0.07

> 40 (> 100)

> 40 (> 100)

 

FTC

0.059 ± 0.041

> 40 (> 100)

> 40 (> 100)

NNRTI

efavirenz

0.005 ± 0.002

> 1 (> 200)

> 1 (> 200)

 

nevirapine

0.22 ± 0.07

> 4 (> 18)

> 4 (> 18)

PPi analog

PFA

126 ± 93

> 400 (> 3)

> 400 (> 3)

  1. a EC50 values were measured in MAGIC-5A cells as described in Methods and are the means ± standard deviation from two or more independent experiments. Numbers in parentheses indicate the fold change in EC50 relative to HIV-1NL4-3. Values shown in bold are significantly different from the corresponding values for HIV-1NL4-3 (p < 0.05, ANOVA with Tukey's multiple comparison test).
  2. b NRTI, nucleoside reverse transcriptase inhibitor. NNRTI, non-nucleoside reverse transcriptase inhibitor. PPi analog, pyrophosphate analog.
  3. c See Abbreviations for drug names.
  4. d XMRV-pseudotyped LtatSN virus. See text for details.